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Background: The chromatin remodeler NAP1L1, which is upregulated in small intestinal neuroendocrine neoplasms
(NENs), has been implicated in cell cycle progression. As p57Kip2 (CDKN1C), a negative regulator of proliferation and a
tumor suppressor, is controlled by members of the NAP1 family, we tested the hypothesis that NAP1L1 may have a
mechanistic role in regulating pancreatic NEN proliferation through regulation of p57Kip2.
Results: NAP1L1 silencing (siRNA and shRNA/lipofectamine approach) decreased proliferation through inhibition of
mechanistic (mammalian) target of rapamycin pathway proteins and their phosphorylation (p < 0.05) in the pancreatic
neuroendocrine neoplasm cell line BON in vitro (p < 0.0001) and resulted in significantly smaller (p < 0.05) and lighter
(p < 0.05) tumors in the orthotopic pancreatic NEN mouse model. Methylation of the p57Kip2 promoter was decreased
by NAP1L1 silencing (p < 0.05), and expression of p57Kip2 (transcript and protein) was upregulated. For methylation of
the p57Kip2 promoter, NAP1L1 bound directly to the promoter (−164 to +21, chromatin immunoprecipitation). In 43
pancreatic NEN samples (38 primaries and 5 metastasis), NAP1L1 was over-expressed in metastasis (p < 0.001),
expression which was inversely correlated with p57Kip2 (p < 0.01) on mRNA and protein levels. Menin was not
differentially expressed.
Conclusion: NAP1L1 is over-expressed in pancreatic neuroendocrine neoplasm metastases and epigenetically
promotes cell proliferation through regulation of p57Kip2 promoter methylation.
Keywords: NAP1L1, Pancreatic neuroendocrine neoplasms, pNETs, Promoter methylation, p57, ProliferationBackground
Pancreatic neuroendocrine neoplasms (pNENs) are an
aggressive form of cancer that are derived from a hetero-
geneous population of endocrine cells [1]. While approxi-
mately 5% of tumors exhibit germ-line mutations in
MEN-1, VHL, NF-1, or TSC [2], the pathogenesis of the
majority of lesions remains ill-understood [3]. Recently,
sequencing of sporadic pNENs identified mutations in
chromatin remodeling genes including menin (in 44% of
the cases) and DAXX/ATRX (43%) [4]. The epigenome
therefore is a potential target in the etiopathology of
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article, unless otherwise stated.One gene that was not mutated was nucleosome
assembly protein 1-like 1 (NAP1L1). NAP1L1 belongs to
a family which is thought to be involved in nucleosome
assembly and exchange of histone H2A-H2B dimmers
[5-7], as well as transcriptional regulation and cell cycle
progression [8]. Inactivation of NAP1 significantly alters
gene expression profiles [9], while deletion of NAP1L2
results in embryonic lethality [10]. NAP1L2, NAP1L3,
and NAP1L5 [11-14] are neuron-specific and play a role
in neuronal differentiation, proliferation, and apoptosis
[15]. NAP1-like proteins have similar activities regarding
nucleosome assembling; NAP1L1, however, displays the
highest disassembly activity [16]. Increased expression of
NAP1L1 may be related to cell growth, as levels of both
NAP1L1 mRNA and protein increase rapidly in conjunc-
tion with cell proliferation in a T-lymphoid cell modelntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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pared with adult liver [18], in hepatoblastoma compared
to healthy adult liver [19], and in 50% of colon cancer
[20]. In addition, NAP1L1 is elevated in malignant adeno-
carcinoids compared to normal mucosa [21] and has been
reported to be over-expressed in small intestinal NENs
[22]. Little, however, is known regarding its expression
and potential role in the pathogenesis of pNENs.
The regulation of cell cycle inhibitors such as the CDK
inhibitor p57Kip2 (CDKN1C) is controlled by members
of the NAP1 family [15], suggesting one mechanism by
which NAP1L1 could regulate proliferation. P57Kip2 is
highly expressed in G0/G1 and decreases during pro-
gression through G1 − S simultaneously with the acti-
vation of cyclin-CDK complexes [23,24]. Accordingly,
over-expression of p57Kip2 induces G1 arrest in cultured
cells [25]. In pancreatic adenocarcinomas, p57Kip2 protein
is decreased in >50% of lesions which correlates with more
aggressive forms [26,27]. In endocrine neoplasms, p57Kip2
expression was absent in 75% of malignant adrenocortical
tumors [28], and in a second study in 47 adrenal tissues,
no p57Kip2 mutations were evident but a decreased ex-
pression was detected in malignant tumors [29].
We hypothesized that NAP1L1 played a role in regulat-
ing cell entry into the S-phase through transcriptional
regulation of factors that controlled neuroendocrine cell
growth and proliferation. We considered that p57Kip2,
as a tumor suppressor, would be silenced in proliferating/
neoplastic neuroendocrine cells as a consequence of
NAP1L1 activity. Since one of the major inherited
genes involved in pancreatic NENs is menin, a known
growth inhibitor and chromatin remodeler [30,31], we
also examined its expression to assess whether it was
associated with NAP1L1 and p57Kip2. We used a dataset
of well-characterized pancreatic NENs (Heidelberg, Yale
collections [32]) as well as the BON cell line [32,33] as a
model to examine the function of NAP1L1.
Results
NAP1L1 knockdown and tumor cell signaling in vitro
Initially, we examined the effect of NAP1L1 silencing in
the BON cell line. NAP1L1 was silenced 3-fold (p < 0.001)
as demonstrated at both protein (Figure 1A) and mRNA
(Figure 1B) levels. This was associated with an increase in
p57Kip2 mRNA (p < 0.01) and protein. While menin mRNA
did not change, protein increased in NAP1L1-silenced cells.
Growth signaling pathways were also altered by NAP1L1
silencing. Specifically, mechanistic (mammalian) target
of rapamycin (mTOR) and phosphorylated mTOR was
reduced in NAP1L1-silenced down cells (Figure 1C).
Consequently, downstream effectors such as eukaryotic
initiation factor 4E-binding protein (4E-BP1) as well as
S6 kinase (S6K1), which mTOR regulates through phos-
phorylation [34], were reduced (Figure 1D,E, p < 0.05).Additionally, mRNA expression of ribosomal proteins
including S24 (RPS24) and ribosomal protein L28 (RPL28)
were also decreased as expected [35] when NAP1L1 was
silenced (Figure 1F, p < 0.05). The ERK pathway was
unaffected (Figure 1B). This suggests that NAP1L1 may
promote proliferation via mTOR signaling.
NAP1L1 and tumor cell proliferation in vitro
To evaluate the expression of NAP1L1, p57Kip2, and
menin during cell proliferation, we first examined protein
expression during the different phases of the cell cycle
(Figure 2A). In proliferating BON cells (2 days of growth
in normal media), quiescent (G0/G1) and cycling (S and
G2/M) cell populations were evenly divided. The shift to
quiescence by 2 days of serum deprivation (80% of the
cells were in G0/G1 phase, Figure 2A) was associated with
decreased NAP1L1 (p < 0.05) and increased P57Kip2
protein expression (p < 0.05) (Figure 2B); menin was
not increased (Figure 2B). Pharmaceutical inhibition of
growth factor signaling pathways with either BEZ235
(targeting mTOR) or GSK1120212 (targeting ERK)
generated similar alterations. Inhibition of these growth
factor signaling pathways tended to decreased NAP1L1
(p = 0.06) and concomitantly increased p57Kip2 mRNA
expression (p < 0.05), while menin did not alter (Figure 2C).
To investigate a role for NAP1L1 in tumor prolifera-
tion, the effect of NAP1L1 knockdown in BON cells was
evaluated in BrdU incorporation assays. Cells were studied
over a 4-day period. By 48 h, there was a significant eleva-
tion in BrdU uptake in non-silenced/normal BON cells
compared to NAP1L1-silenced BON cells (Figure 2D,
p < 0.0001, approximately 40-fold) as well as a marked
decrease in the number of cells in these experiments
(Figure 2D).
NAP1L1 and tumor cell proliferation in vivo
We next examined whether NAP1L1-silencing reduced
tumor formation in an orthotopic pNEN mouse model.
Transfection with shRNA was associated with a 70% in-
ternalization of the plasmid by fluorescence microscopy
(Figure 3A). Three weeks after BON cell implantation
(1.5 × 106 cells, viability approximately 90%) into the
pancreas tail at laparotomy, all mice in the control group
(n = 4) had developed palpable tumors on the left upper
side of the stomach. In contrast, only two of the five
mice, injected with NAP1L1 knockdown cells, had tumors
at 4 weeks. Both were small tactile tumors. After 6 weeks,
we euthanized all nine mice (four with injection of control
BON cells and five with injection of NAP1L1 knockdown
BON cells) and found liver metastases in two of the
four mice in the control group; all four mice had add-
itional peritoneal metastases. None of the knockdown
group exhibited any macroscopic evidence of metastases
(Figure 3B). Pancreatic tumors in the control group were
Figure 1 Effect of NAP1L1 silencing. Effect of NAP1L1 silencing on p57Kip2 and menin expression as well as on the mTOR pathway in BON
cells. An effective NAP1L1 knockdown (approximately 3-fold, *p < 0.001) increased p57Kip2 protein (A) and mRNA (B) (#p < 0.01), while menin was
increased at protein level only (A and B). The ERK pathway was unaffected in NAP1L1-silenced cells, while total mTOR as well as phosphorylated
mTOR decreased in NAP1L1 silenced BON cells (C). The mTOR downstream effectors eukaryotic initiation factor 4E-binding protein (4E-BP1) and
S6 kinase (S6K1) also showed less protein expression and decreased phosphorylation when NAP1L1 was absent (D and E) (*p < 0.05). MRNA levels
of the two ribosomal proteins RPS24 and RPL28, as a measure of mTOR activity, were also decreased in NAP1L1 knockdown cells (*p < 0.05),
indicating that NAP1L1 may promote mTOR signaling (F). 4E-BP1, lower band. Mean ± standard error of mean (SEM).
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0.95 g) in comparison to the NAP1L1 knockdown group
(17.48 ± 4.12 mm3 and 1.57 ± 0.29 g, p < 0.05) (Figure 3C,
D). At an mRNA level, a decreased NAP1L1 expression in
knockdown tumors (p < 0.05) was confirmed (Figure 3E).
Blood samples demonstrated a lower chromogranin A
(CgA) serum expression in mice which had been injected
with NAP1L1-knockdown cells (Figure 3F, p < 0.05) sug-
gesting that CgA may, as in humans [36], be a marker of
tumor burden. Its expression also correlated with tumor
size (r = 0.88, p < 0.01) and weight (r = 0.9, p < 0.01) (data
not shown). Histopathologically, a decrease in NAP1L1 ex-
pression was noted in knockdown tumors while the protein
was highly expressed in liver metastases (Figure 3G). Ex-
pression of CgA was similar in normal and NAP1L1 knock-
down tumors; metastases expressed less CgA (Figure 3G).
NAP1L1 controls p57Kip2 expression by direct binding to
its promoter
To investigate mechanisms by which NAP1L1 regu-
lated proliferation, we examined the methylation statusof the p57Kip2 promoter region in normal and NAP1L1-
silenced BON cells. As demonstrated (Figure 4A), a highly
methylated (=silenced p57Kip2) promoter was detected
in untreated BON cells. In contrast, the promoter was
significantly less methylated (p < 0.05) in NAP1L1-
silenced cells which suggested that NAP1L1 may be
necessary for the maintenance of p57Kip2 promoter
methylation and therefore inhibition of p57Kip2 tran-
scription. We used ChIP analysis to examine whether
NAP1L1 directly interacted with the p57Kip2 pro-
moter. In normal growing BON cells, NAP1L1-bound
DNA fragments contained the p57Kip2 promoter re-
gion (−164 to +21) (Figure 4B). In low-proliferating
BON cells (2-day serum deprivation), no binding of
NAP1L1 to the p57Kip2 promoter was detected. We
interpret these results to provide an explanation for
the increased p57Kip2 protein expression (no NAP1L1
binding and therefore inhibition, coupled to activa-
tion through known p57Kip2 transcriptional regula-
tors, e.g., HDACI/II) [37] in serum-deprived BON cells
(Figure 2B).
Figure 2 (See legend on next page.)
Schimmack et al. Epigenetics & Chromatin 2014, 7:15 Page 4 of 12
http://www.epigeneticsandchromatin.com/content/7/1/15
(See figure on previous page.)
Figure 2 The effect of NAP1L1 on tumor cell proliferation in vitro. In proliferating BON cells, 56% were in the quiescent cell phase (G0/G1)
and 44% in the proliferating cell phase (S and G2/M). After two days of serum deprivation, 80% of the cells were quiescent (A). A decrease of
NAP1L1 (*p < 0.05) and an increase of p57Kip2 (*p < 0.05) protein expression were evident (B). Inhibiting proliferation by targeting the mTOR
pathway (BEZ235) and ERK pathway (GSK1120212) resulted in a similar pattern of expression: NAP1L1 tended to be decreased ((*) p = 0.06) and
p57Kip2 was increased (*p < 0.05) while menin did not alter (C). BON cells without NAP1L1 did not grow (*p < 0.0001) and exhibited decreased
cell numbers (D). Mean ± SEM.
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normal and neoplastic pancreas
To evaluate whether the in vitro and in vivo mechanistic
observations were clinically relevant, we screened
NAP1L1, p57Kip2, and menin in ten normal pancreas
and 43 pNEN samples. NAP1L1 mRNA was over-
expressed in pNEN primaries (p < 0.01) and pNEN metas-
tasis (p < 0.01) compared to normal pancreas (Figure 5A,
Kruskal-Wallis p < 0.001). In contrast to these findings,
p57Kip2 mRNA was almost completely downregulated in
metastases versus normal pancreas (Figure 5B, p < 0.01).
Menin mRNA expression was not different in this pNEN
sample set compared to normal tissue (Figure 5C). In
addition, we identified a positive correlation between
NAP1L1 mRNA levels and Ki67 (r = 0.64, p < 0.0001), CgA
(r = 0.42, p < 0.001), Chromogranin B (r = 0.61, p < 0.0001),
and the pNEN biomarker, INA [32] (r = 0.64, p < 0.0001)
(data not shown). NAP1L1 expression was also positively
correlated with tumor size (Figure 5D, Spearman’s r = 0.4,
p < 0.05). The mRNA results were confirmed on protein
level (Figure 5E): NAP1L1 was over-expressed in pNEN
primaries (p < 0.05) and pNEN metastasis (p < 0.05) com-
pared to normal pancreas (Figure 5F,D), while p57Kip2 pro-
tein levels were higher in normal pancreas than in pNENs
(p < 0.05, Figure 5G,D). Menin protein expression was also
not different in this pNEN sample set compared to normal
pancreatic tissue (Figure 5H,D).
Discussion
The etiology and tumorigenesis of pancreatic NENs, which
are the most aggressive form of gastroenteropancreatic
NENs [38], remain poorly understood. Epigenetic modifica-
tions are unarguably one of the major mechanisms for
pNEN pathogenesis [4]. In the present study, we examined
the expression and function of chromatin modulator
NAP1L1 in pancreatic NENs. While other NAP1 family
members, e.g., NAP1L2, NAP1L3, and NAP1L5 [11-14] are
well known to be neuron-specific and play a role in pro-
liferation [15] and the NAP1 family is associated with
transcriptional regulation [8], our current results define
a role for NAP1L1 in the transcriptional regulation of
pancreatic neuroendocrine neoplasm cell cycle progres-
sion. Specifically, our results highlight a role for this
family member as an inhibitor of p57Kip2.
The current studies demonstrate (1) that NAP1L1 was
over-expressed, while p57Kip2 was downregulated inpNENs, (2) that NAP1L1 is involved in the mTOR
pathway signaling, (3) that NAP1L1 was essential for
proliferation in vitro and in an orthotopic pNEN mouse
model, and (4) that one mechanism of NAP1L1-mediated
cell proliferation control may occur through inhibition of
p57Kip2 transcription.
P57Kip2 has many functions; as it can arrest the cell
cycle, promote apoptosis, and inhibit angiogenesis as
well as its downregulation in many cancers [39], it quali-
fies as a tumor suppressor. It is also important in embryo-
genesis; p57Kip2-null mice exhibit high neonatal mortality
with severe developmental defects [40]. In neoplasia,
downregulation of p57Kip2 promotes cell migration, and
invasion in human nasopharyngeal carcinoma cells [41]
and decreased expression were associated with poor
postsurgical survival time and lymphatic metastasis in
lung cancer [42] as well as in other cancer types [25,39],
e.g., in hepatocellular [43] or pancreatic [27] carcinoma.
Our studies confirmed downregulation of p57Kip2 in
pNENs and suggest one mechanism for this phenomenon.
The promoter region of the p57Kip2 gene is rich in CpG
islands and promoter methylation is a well-described
mechanism to explain attenuated expression in cancers
[39]. In a panel of tumor cell lines and primary cancer
cells, dense p57Kip2 promoter CpG methylation was iden-
tified at the transcription start site [44]. We determined a
role for NAP1L1 in the regulation of p57Kip2 promoter
methylation in BON cells by direct promoter binding
of NAP1L1. NAP1-like proteins have previously been
reported to control gene expression through histone
H3 acetylation [15]. Methylation, through a NAP1L1-
complex, is therefore a novel mechanism for p57Kip2
transcriptional control that may be applicable to other
neoplasia. This is supported by studies with demethy-
lating agents (5-azacytidine or 5-aza-2′-deoxycytidine)
which results in p57Kip2 re-expression or over-expression
in several experimental cancer models [45,46]. Our obser-
vations suggest a direct link between NAP1L1 and p57Kip2.
Targeting NAP1L1 (through silencing) increased the
expression of p57Kip2 and resulted in significant de-
creases in both DNA synthesis as well as metastasis
in vivo. Mechanistically, NAP1L1 bound to SP1/CTIP2
sites that are involved in HDAC-mediated transcriptional
regulation of p57Kip2 [37]. These sites are dissimilar to
those identified for NAP1L2 binding in the promoter
region in ES-derived differentiated neurons [15]. As
Figure 3 (See legend on next page.)
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Figure 3 Impact of NAP1L1 silencing of tumor growth in an orthotopic pNEN mouse model. After having established stable NAP1L1
knockdown BON cells (confirmation of shRNA internalization by fluorescence microscopy (A) and thereafter puromycin-selection), we injected
1.5 × 106 transfected cells in 100 μl PBS into the pancreas tail of nine Ns/J-mice by flank-laparotomy (CON = 4 mice, KD = 5 mice). Six weeks after
pancreas injection, necroscopy identify large tumors with metastases in control injected mice (B), while KD-injected mice had smaller (C) (*p < 0.05)
and lighter (D) (*p < 0.05) tumors that were all localized. KD tumors expressed less NAP1L1 than controls (E and G). Circulating chromogranin A (CgA)
levels were also decreased in serum of KD mice (F) (*p < 0.05), and expression of this marker was lower in the liver metastases (G). Mean ± SEM.
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through increased levels of acetylated histone H3K9/14,
we conclude that NAP1L1 may inhibit transcription either
by a similar mechanism or through inhibition of SP1-
mediated activity [47].
The principal growth factor signaling pathway also
affected by NAP1L1-silencing was the mTOR pathway.
We identified that NAP1L1 knockdown both reduced
phosphorylation of downstream mTOR effectors including
4E-BP1 as well as S6K1 and was associated with a de-
creased ribosomal RNA expression, all markers consistent
with mTOR inhibition [35]. The ERK pathway, in con-
trast, was unaffected (Figure 1B). This suggests that
NAP1L1 may promote proliferation via mTOR signaling.
Since mutations of this pathway have been reported in
15% of pNENs [4], a role for NAP1L1 in this pathway may
be of clinical relevance.
Menin, also a tumor suppressor, is one of the gene
products predominantly mutated in pNENs [4,30]. The
mechanism(s) of menin-driven tumor pathogenesis,
however, remain unclear [2,48]. Menin can function as
a histone-methyltransferase and is reported to have anFigure 4 p57Kip2 promoter methylation and NAP1L1 binding. Genomic
treated with bisulfate, which converted cytosine of unmethylated p57Kip2 promo
performed using two p57Kip2 promoter primers (forward first primer, CGCCAATC
reverse primer, GCCAGGCCTGAGCGAGCGAG). Unmethylated p57Kip2 promoter r
(*p< 0.05) indicating that NAP1L1 controls p57Kip2 expression by methylation of
the Pierce Agarose ChIP Kit (Thermo Scientific) according to the manufacturer’s
was evident in normal growing BON cells; non-proliferating cells did not silen
expression in NAP1L1-bound DNA fragments is shown in relation to the contanti-proliferative regulatory effect in pancreatic islet
cells through histone H3K4 methylation and regulation
of cell cycle inhibitors [49]. We anticipated that menin
expression would be decreased in BON cells and clinical
samples. We could not identify an altered expression in
clinical samples or in the cell line (consistent with previ-
ous reports [50,51]). One reason may be the absence of
MEN1 mutations in our sample set. A second reason
might be that despite a mutation of one menin allele,
menin mRNA is detectable by PCR while the menin-
antibody used (Cell Signaling Technology) recognizes
all three isoforms of menin. This suggests that menin
expression is not linked to NAP1L1-mediated effects.
However, we did identify that menin protein expression
was increased in NAP1L1 silenced cells which suggests
that NAP1L1 may function to negatively regulate menin
expression. This potentially identifies an additional role
for NAP1L1 in pNEN pathogenesis.
Conclusions
Our data identifies that NAP1L1 epigenetically promotes
tumor cell proliferation in pancreatic neuroendocrineDNA of normal BON cells and NAP1L1 silenced BON cells were
ter into uracil. Methylation-specific polymerase chain reaction (MSPCR) was
GCCGTGGTGTTG; forward second primer, ACTACATTATGCTAATCGCG;
esulted in low PCR products as demonstrated for NAP1L1-silenced cells (A)
its promoter. In chromatin immunoprecipitation (ChIP) experiments, using
instructions, a direct binding of NAP1L1 protein to the p57Kip2 promoter
ce the p57Kip2 promoter (B) (*p < 0.05). The calculated promoter
rol. Mean ± SEM.
Figure 5 NAP1L1, p57Kip2, and menin expression in pancreatic neuroendocrine neoplasms compared to normal pancreatic tissue.
NAP1L1 was increased at mRNA level (A) (Kruskal-Wallis p < 0.001) in pNEN primaries (#p < 0.01) and metastases (*p < 0.01) and expression
correlated with tumor size (D) (r = 0.42, p < 0.05). In contrast, p57Kip2 mRNA was downregulated in pNEN metastases (B) (*p < 0.01). Menin was not
differently expressed in pNEN in comparison to normal tissue in this sample set (C and H). Western blot analysis (E) confirmed elevated NAP1L1
protein levels (F) (*p < 0.05) and downregulated expression of p57Kip2 in pNENs (G) (*p < 0.05). Mean ± SEM.
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the tumor suppressor p57Kip2; the principal mechanism is
via p57Kip2 promoter methylation. This turns NAP1L1
into a promising target for anti-cancer therapy.
Methods
Cell lines
To investigate mechanistic roles and the importance of
NAP1L1 in proliferation, we used the adherent human
metastasized pancreatic neuroendocrine neoplasm (NEN)
cell line, BON [33], authenticated by STR (Genetica DNA
Laboratories, Cincinnati, OH, USA). The cells were
cultivated in medium containing RPMI 1640, Hams’
F12 (Gibco, Grand Island, NY, USA; 1:1 ratio), 10%
FBS and penicillin/streptomycin (100 IU/ml) in 75 cm2
flasks (Sarstedt, Newton, NC, USA) as described [32].NAP1L1 knockdown
To assess the role of NAP1L1 in cell proliferation, we
seeded 1.6 × 105 BON cells/well in 6-well plates (Falcon,
BD, Franklin Lakes, NJ, USA) and silenced NAP1L1 using
reverse transfection with siRNA (sequence GGUAGAA
ACACCAACAGGAUACAUU, 140 pmol/well) and Lipo-
fectamine RNAiMAX (Invitrogen, Carlsbad, CA, USA).
We confirmed the knockdown using PCR and Western
blot after 24–96 h. Control cells were treated with Lipo-
fectamine and scrambled siRNA.
Proliferation assay
To investigate the role of NAP1L1, p57Kip2, and menin in
cell proliferation, we first cultured BON cells (2.5 × 105/
well) in 6-well plates (Falcon, BD, Franklin Lakes, NJ,
USA) under normal conditions with (normal/logarithmic
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harvested them after 2 days for FACS (to determine the
cell cycle kinetics of those BON cells, see FAC-sorting sec-
tion) and protein isolation. In a second set of experiments,
we used a BrdU (bromodeoxyuridine) chemiluminescence
ELISA (Roche Diagnostics, Indianapolis, IN, USA) to
investigate the proliferation of normal and NAP1L1-
silenced BON cells according to the manufacturers’ in-
structions. Briefly, NAP1L1-silenced BON cells were
labeled in 12-well plates (Falcon) with BrdU solution
and incubated for 3 h. After fixation and DNA denatur-
ation, BrdU incorporation, as a measurement of cell div-
ision, was quantitated using a chemiluminescence assay
(GLOMAX Luminometer, Promega, Madison, WI, USA).
Inhibition of the PI3K/mTOR and MAP-kinase pathway
We evaluated growth signaling and expression of NAP1L1,
p57Kip2, and menin using selective pharmaceutical com-
pounds that specifically inhibited growth-signaling-pathway
kinases. We seeded BON cells (3 × 105 cells/well) in
6-well plates (Falcon) for 24 h and treated these cells
with GSK1120212 [MAPK pathway inhibitor (target
MEK1/2) − 10−7 M) and BEZ235 [mTOR pathway in-
hibitor (target PI3K/PKB) − 10
−8 M) for 24 h prior to
mRNA collection. Cells were harvested by adding
TRIZOL® (Invitrogen, Carlsbad, CA, USA) (see Isolation of
RNA and genomic DNA, reverse transcription, and quanti-
tative PCR section).
FAC-sorting
To quantify the cell cycle phases of BON cell after
serum deprivation versus logarithmic growth (see Prolif-
eration assay section), we harvested those BON cells and
after 15 min incubation with propidium iodide/PBS
(1:50, Roche, Indianapolis, IN, USA) conducted flow
cytometry (BD FACS Aria Cell Sorter, BD Biosciences,
Bedford, MA, USA). Cell cycle alterations were analyzed
using FloJo Software 31 (TreeStar, Mountain View, CA,
USA) [52].
Orthotopic murine xenograft model
To assess the role of NAP1L1 in tumor cell proliferation
in vivo, we attempted to establish a permanent NAP1L1
knockdown BON cell line by transfection of a NAP1L1-
shRNA plasmid containing puromycin resistance gene
and GFR luminescence (GeneCopoeia, Rockville, MD,
USA) via Lipofectamine RNAiMAX (Invitrogen). Because
proliferation of those cells was decreased so significantly
following transfection (see Figure 2D), we could not cul-
ture the necessary number of cells for in vivo experiments.
As an alternative, we grew BON cells in 75 cm2 flasks
(Sarstedt) and transfected them in these flasks overnight
in antibiotic-free medium. After confirming the internal-
ization of the plasmid through fluorescence microscopy(488 nm), stable shRNA clones were selected via growth
media containing 3 μg/ml puromycin (Invitrogen) and
cells were harvested after 48 h (viability 77%–90%). We
injected 1.5 × 106 of the transfected cells or control BON
cells (Lipofectamine treatment, viability >90%) in 100 μl
PBS into the pancreas tail of nine Ns/J-mice (Jackson
Laboratory, Bar Harbor, ME, USA) by flank-laparotomy
under anesthesia [53]. All mice were euthanized 6 weeks
after BON cell implantation, and circulating blood and
tumor tissue were collected. All animals were treated ac-
cording to IRB standards of the Yale University.
Human sample collection
The collection of pancreatic tissue from patients with
pNENs (n = 43) and normal pancreas (n = 10) was ob-
tained according to the Ethics Committee requirements
for the University of Heidelberg, Germany and an IRB
protocol at Yale University [32]. Quality control was
assured by a pathologist experienced with NEN histopath-
ology. Only samples in which histology demonstrated
more than 70% tumor were included. As only five patients
had died, survival analysis was not undertaken.
Protein extraction and western blot analysis
Tissue (1 × 2 mm) or cell line lysates were manually
homogenized (PYREX homogenizer; VWR, Radnor, PA,
USA) and prepared as previously described [32]. Super-
natant protein was quantified (Pierce BCA protein assay
kit; Thermo Scientific, Rockford, IL, USA), total protein
lysates (15 μg) were denaturated in SDS sample buffer,
separated on an SDS-PAGE gel [10% or 4%–20% (mTOR
and 4E-BP1)], and transferred to a PVDF membrane
(Bio-Rad, Hercules, CA, USA; pore size 0.45 mm). Primary
antibodies included anti-NAP1L1 (Abcam, Cambridge,
MA, USA), anti-p57Kip2, anti-menin-1, anti-phospho-
ERK, anti-ERK, anti-phospho-mTOR, anti-mTOR, anti-
phospho-S6K1, anti-S6K1, anti-phospho-4E-BP1, and
anti-4E-BP1 (all from Cell Signaling Technology, Beverly,
MA, USA). Immunodetection was performed using
Western Lightning™ Plus-ECL (PerkinElmer, Waltham,
MA, USA). Protein levels were confirmed with β-actin
(Sigma-Aldrich, St. Louis, MO, USA). The optical density
of the appropriately sized bands was measured using
ImageJ software (NIH, Bethesda, MD, USA). The ratio
between target protein expression and control protein
was calculated.
Isolation of RNA and genomic DNA, reverse transcription,
and quantitative PCR
Messenger RNA was extracted from each tissue samples
(or cell lines) using TRIZOL® (Invitrogen, Carlsbad, CA,
USA) and cleaned (RNeasy kit, Qiagen, Valencia, CA,
USA). After conversion to cDNA (high-capacity cDNA
Archive Kit, Applied Biosystems, Carlsbad, CA, USA),
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Assays-on Demand™ and the ABI 7900 Sequence Detec-
tion System. Primer sets were all obtained from Applied
Biosystems. PCR data was normalized using the ΔΔCT
method; ALG9 was used as a housekeeping gene [54].
The extraction of genomic DNA was performed using
the MasterPure Complete DNA and RNA Purification
Kit (EPICENTRE, Madison, WI, USA) according to the
manufacturers’ instructions and quantified by Nanodrop
(Thermo Scientific).
p57Kip2 promoter methylation
To investigate the status of p57Kip2 promoter methylation,
we treated genomic DNA of normal BON cells and
NAP1L1-silenced BON cells with bisulfate, which caused
conversion of unmethylated cytosines into uracil. This was
undertaken using the Methyl Code Bisulfite Conversion Kit
(Invitrogen) according to the manufacturers’ instructions.
MSPCR was performed using two primers which bound to
the p57Kip2 promoter region (NCBI reference sequence
NG_008022.1) (first forward primer, CGCCAATCGCC
GTGGTGTTG [−164 to −141]; second forward primer,
ACTACATTATGCTAATCGCG [−126 to −107]; reverse
primer, GCCAGGCCTGAGCGAGCGAG) [+2 to +21]).
The forward primers encompass SP1 and CTIP2 binding
sites involved in HDAC-mediated transcriptional regula-
tion [37]. Unmethylated promoter resulted in low PCR
products in this assay.
Chromatin immunoprecipitation
To examine whether NAP1L1 directly bound to the
p57Kip2 promoter, we performed ChIP using the Pierce
Agarose ChIP Kit (Thermo Scientific). Briefly, we fixed
the crosslinks between DNA and protein by formaldehyde,
lysed the cells, and digested chromatin using micrococcal
nuclease. Of these DNA fragments, 10% was used as input
control. After immunoprecipitation with a ChIP-grade-
NAP1L1-antibody (Santa Cruz Biotechnology, Santa Cruz,
CA, USA), DNA fragments were purified and qPCR per-
formed using primers for detecting the p57Kip2 promoter
(see above). We used normal rabbit IgG as negative and
anti-RNA polymerase II antibody and GAPDH promoter
primers as positive controls. The p57Kip2 promoter expres-
sion in NAP1L1-bound DNA fragments was calculated
relative to the control.
Statistical evaluation
All statistical analyses were performed using Microsoft
Excel and Prism 5 (GraphPad Software, San Diego, CA,
USA). Comparisons between more than two groups
were performed using the Kruskal-Wallis test, followed
by the Dunn’s post hoc test where appropriate. Binary
comparisons were made using a 2-tailed Mann–Whitney
U test. Correlations were undertaken using Spearman’scorrelation. A p value of <0.05 was designated as signifi-
cant. Statistical significance is indicated by an asterisk and
described in the figure legends. Bars without an asterisk
did not reach significance.
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